Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453, Spartalizumab, and SRS in Recurrent GBM
NCT03961971Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sabatolimab in glioblastoma multiforme (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Serious Adverse Events at 12 weeks. Started Feb 2020; status: completed.
02
Drugs
sabatolimab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03961971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961971.